@ndesai2005 @GSCollins https://t.co/hMWJRIpYDS “There was not a statistically significant interaction between GC score and hormone treatment effect for DM (HR, 1.03; 95% CI, 0.82-1.30; P = .80), PCSM (HR, 1.13; 95% CI, 0.81-1.57; P = .46), or OS (HR, 0.97;
De los estudios más interesantes del año en #GUOnc
Open Access UCL Research: Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial https://t.co/EJ9AEOIYR6
RT @JAMAOnc: Ancillary study of men w #ProstateCancer randomized to placebo vs hormone therapy in NRG/RTOG 9601 clinical trial of salvage r…
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial | Cancer Biomarkers | JAMA Oncology | JAMA Network https://t.co/Al5W6NvH0r
Ancillary study of men w #ProstateCancer randomized to placebo vs hormone therapy in NRG/RTOG 9601 clinical trial of salvage radiation, Decipher genomic classifier stratifies men at risk for mets, cancer-specific mortality, & overall surv https://t.co/
RT @claysmithmd: @SbrtSean We’ve (@AmarUKishan) been using decipher to decide +/- ADT (typically using 6 months of Lupron unless they refus…
@SbrtSean We’ve (@AmarUKishan) been using decipher to decide +/- ADT (typically using 6 months of Lupron unless they refuse or if otherwise contraindicated) in the salvage setting based on the recent study https://t.co/eoBxKL5gSb
So much important work underway! Using #Decipher genomic testing, the @felixfengmd-led study of an RTOG 9601 cohort found that all #prostatecancer patients with rising PSA levels after surgery may not benefit equally from adding hormone therapy to sRT.
@felixfengmd et al featured on NCI https://t.co/z3FzUk3tE7 re: the utility of Decipher testing in determining who should get hormone therapy during salvage radiation for recurrent prostate cancer https://t.co/kfBKQSQGgU https://t.co/VexlSZsskY
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
Congrats to Darby Thompson, @decipher_bio & @Veracyte on this publication in @JAMAOnc, the first level-1 validation of the Decipher genomic classifier using a large, randomized, placebo-controlled, prospective clinical trial. https://t.co/PTxh981qov
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial @JAMAOnc https://t.co/ZJmJtM2jPW @jama oncology
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial https://t.co/dJYtRPTCLZ
Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms https://t.co/mGsoRMhrsj https://t.co/dJYtRPTCLZ
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
Important study by @felixfengmd @Davicioni et al @jamaonc highlighting novel biomarker in #ProstateCancer @PCFnews @PCF_Science @NRGonc
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
Lurking for years... but look who just joined the conversation @felixfengmd! Welcome mentor and friend 🤙🏽
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @NatRevClinOncol: The Decipher genomic classifier is independently associated with risk of metastasis, cancer-specific mortality & OS i…
The Decipher genomic classifier is independently associated with risk of metastasis, cancer-specific mortality & OS in men with biochemical recurrence of prostate cancer after surgery, suggesting promise as a biomarker to inform hormone therapy decisi
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
Congrats @felixfengmd and Phuoc Tran!
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
RT @felixfengmd: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMA…
Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/r3CwABjzax via @JAMAOnc part of @JAMANetwork
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. 𝙅𝘼𝙈𝘼 𝙊𝙣𝙘𝙤𝙡. #ProstateCancer https://t.co/a5cnywAzTD
RT @DrAndrewLoblaw: What do people give as adjuvant with postop RT most often? 6mo LHRHa? 24mo LHRHa? 24mo bicalutamide 150mg? Or Depends o…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @DrAndrewLoblaw: What do people give as adjuvant with postop RT most often? 6mo LHRHa? 24mo LHRHa? 24mo bicalutamide 150mg? Or Depends o…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @DrAndrewLoblaw: What do people give as adjuvant with postop RT most often? 6mo LHRHa? 24mo LHRHa? 24mo bicalutamide 150mg? Or Depends o…
RT @decipher_bio: Hot off the presses from @JAMAOnc: Decipher validates as an independent predictor of overall survival in RTOG 96-01, a Ph…
RT @JAMAOnc: Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/fpAqYWZUUJ #onlinefirst
Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/fpAqYWZUUJ #onlinefirst
Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/TQ7D5zituM via @JAMAOnc part of @JAMANetwork
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @decipher_bio: Hot off the presses from @JAMAOnc: Decipher validates as an independent predictor of overall survival in RTOG 96-01, a Ph…
RT @decipher_bio: Hot off the presses from @JAMAOnc: Decipher validates as an independent predictor of overall survival in RTOG 96-01, a Ph…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @whallradonc: Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG…
RT @DrAndrewLoblaw: What do people give as adjuvant with postop RT most often? 6mo LHRHa? 24mo LHRHa? 24mo bicalutamide 150mg? Or Depends o…
RT @DrAndrewLoblaw: What do people give as adjuvant with postop RT most often? 6mo LHRHa? 24mo LHRHa? 24mo bicalutamide 150mg? Or Depends o…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
What do people give as adjuvant with postop RT most often? 6mo LHRHa? 24mo LHRHa? 24mo bicalutamide 150mg? Or Depends on situation? If easier I can do proper poll...
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @decipher_bio: Hot off the presses from @JAMAOnc: Decipher validates as an independent predictor of overall survival in RTOG 96-01, a Ph…
RT @decipher_bio: Hot off the presses from @JAMAOnc: Decipher validates as an independent predictor of overall survival in RTOG 96-01, a Ph…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
A promising genomic biomarker to risk stratify men with prostate cancer to better enable hormone therapy treatment decisions for biochemical recurrence after surgery. Via @JAMAOnc https://t.co/deKidoDopL & https://t.co/JFixoKUIVr
RT @JAMAOnc: Ancillary study of men w #ProstateCancer randomized to placebo vs hormone therapy in NRG/RTOG 9601 clinical trial of salvage r…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
Validation of a 22-Gene Genomic Classifier in Recurrent Prostate Cancer https://t.co/1P9PdaTezT via @JAMAOnc part of @JAMANetwork
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial | Cancer Biomarkers | JAMA Oncology | JAMA Network https://t.co/E3ijSxJuKq
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
New article: Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. https://t.co/qrt7KCbsZV #prostatecancer #oncology https://t.co/sS0zSVxMc3
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent #ProstateCancer An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial https://t.co/97DJNYB1ed #Cancer
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @RTendulkarMD: Congrats @felixfengmd on this paper out today in @JAMAOnc validating Decipher in RTOG 9601 https://t.co/UHvA85vcIG https:…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @SeanMcGuireMD: Congrats to @felixfengmd and colleagues on the first prospective validation of the Decipher 22 gene Genomic Classifier f…
RT @DrSpratticus: Amazing and must read editorial out too! Well done Dr McGuire.
Amazing and must read editorial out too! Well done Dr McGuire.
RT @JAMAOnc: Ancillary study of men w #ProstateCancer randomized to placebo vs hormone therapy in NRG/RTOG 9601 clinical trial of salvage r…